Evidence map›Paper›PMID 31372036›Full record

ArticleCancer management and research2019

Radiation therapy-induced reactive oxygen species specifically eliminates CD19

Weiwei Li, Luman Wang, Chunying Shen, Tingting Xu, Yiwei Chu, Chaosu Hu

Open access · goldAbstract read
In one paragraph

Article in Cancer management and research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Weiwei Li *Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.
Luman Wang *Department of Immunology, School of Basic Medical Sciences, and Institute of Biomedical Sciences, Fudan University, Shanghai 200032, People's Republic of China.
Chunying ShenDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.
Tingting XuDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.
Yiwei ChuDepartment of Immunology, School of Basic Medical Sciences, and Institute of Biomedical Sciences, Fudan University, Shanghai 200032, People's Republic of China.
Chaosu HuDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.
Shanghai Medical College of Fudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeNasopharyngeal carcinoma (NPC) is one of the most common head and neck cancers and is thought to be related to the mucosal immune system. Radiation therapy (RT) is the primary treatment for NPC due to the high radiosensitivity of cancer cells. However, little is known about the impact of RT on the mucosal immune system. PATIENTS AND

methodsIn this study, the expression of immune markers CD19, CD24, CD27, CD8, and IgA before and after RT, were analyzed using flow cytometry. Cytokines were assessed using the enzyme-linked immunosorbent assay. Reactive oxygen species (ROS) was assayed by flow cytometry and fluorescence staining using 2',7' -dichlorofluorescein diacetate.

resultsWe found that primary NPC patients had a significant increase in CD19

conclusionThese findings suggest that RT may regulate the immune system and opens up new avenues for the utilization of immune-radiotherapy in NPC.

Indexed as

B cellsIgAnasopharyngeal carcinomaradiation therapyregulatory immune cells

Identifiers

PMID31372036
PMCPMC6635828
OpenAlexW2954894220

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.